Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.25 USD
Change Today -0.07 / -5.30%
Volume 1.9M
AVXL On Other Exchanges
Symbol
Exchange
Berlin
As of 8:10 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

anavex life sciences corp (AVXL) Snapshot

Open
$1.33
Previous Close
$1.32
Day High
$1.34
Day Low
$1.23
52 Week High
08/6/15 - $1.67
52 Week Low
12/1/14 - $0.15
Market Cap
150.6M
Average Volume 10 Days
2.7M
EPS TTM
$-0.32
Shares Outstanding
120.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ANAVEX LIFE SCIENCES CORP (AVXL)

Related News

No related news articles were found.

anavex life sciences corp (AVXL) Related Businessweek News

No Related Businessweek News Found

anavex life sciences corp (AVXL) Details

Anavex Life Sciences Corp., a biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of Alzheimer’s disease, central nervous system diseases, and pain and various cancers. Its lead drug candidates include ANAVEX 2-73 and ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), which is in a Phase IIa clinical trial for the treatment of Alzheimer’s disease. The company’s product candidates also include ANAVEX 3-71, a drug candidate that is effective in very small doses against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice via sigma-1 receptor activation and M1 muscarinic allosteric modulation; ANAVEX 1-41, a sigma-1 agonist for neuroprotective application; and ANAVEX 1037, ANAVEX 1079, and ANAVEX 1519 for the treatment of pain and various cancers. Anavex Life Sciences Corp. was founded in 2006 and is headquartered in New York, New York.

4 Employees
Last Reported Date: 07/8/15
Founded in 2006

anavex life sciences corp (AVXL) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $640.0K
Compensation as of Fiscal Year 2014.

anavex life sciences corp (AVXL) Key Developments

Anavex Life Sciences Corp. Reports Consolidated Financial Results for the Third Quarter and Nine Months Ended June 30, 2015

Anavex Life Sciences Corp. reported consolidated financial results for the third quarter and nine months ended June 30, 2015. For the quarter, the company reported operating loss of $1,512,960 against $998,833 a year ago. Net loss was $4,240,244 or $0.06 per basic and diluted share against $1,009,090 or $0.03 per basic and diluted share a year ago. For nine months, the company reported operating loss of $3,141,977 against $2,329,608 a year ago. Net loss was $6,751,821 or $0.11 per diluted share against $1,669,313 or $0.04 per diluted share a year ago.

Anavex Life Sciences Corp. to Report Q3, 2015 Results on Aug 17, 2015

Anavex Life Sciences Corp. announced that they will report Q3, 2015 results on Aug 17, 2015

Anavex Life Sciences Corp. Receives Grant from the Michael J. Fox Foundation for Parkinson’S Research

Anavex Life Sciences Corp. announced that it has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to develop ANAVEX 2-73 for the treatment of Parkinson’s disease. The MJFF grant is expected to fully fund a preclinical study on the effect of ANAVEX 2-73 in a Parkinson’s disease animal model, which seeks to provide a solid dataset that will justify moving forward to clinical development in Parkinson’s. The study may also provide further evidence for the involvement of sigma-1 receptors in potentially disease-modifying therapies for Parkinson’s disease. As a potential platform drug and the Company’s lead therapeutic, ANAVEX 2-73 targets misfolded proteins central to many neurodegenerative diseases, including Parkinson’s and Alzheimer’s. It is believed to enhance the body's own cellular defense mechanisms through both sigma-1 and muscarinic receptors to return diseased cells to a pre-diseased or “homeostatic” state.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AVXL:US $1.25 USD -0.07

AVXL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AVXL.
View Industry Companies
 

Industry Analysis

AVXL

Industry Average

Valuation AVXL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 17.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANAVEX LIFE SCIENCES CORP, please visit www.anavex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.